Aa
APPROVED - Update on drugs!
So excited - today got approval for BOTH Solvaldi and Olysio to be provided to me for a 12 week treatment using just these 2 drugs! As you might recall from my previous posts that my Hep Dr. believes that this combo will be the perfect cocktail for SUCCESS! Tomorrow marks exactly 1 year since I stopped the last treatment at 24 weeks of Riba, Victrelis and Pegasus. HORRIBLE side effects, blood transfusions and detectable AGAIN at the post 12 week mark. It actually took me 6 - 7 months to shed all the side effects and feel normal again. That was my 2nd attempt to SVR and at 61 years old I am really praying this treatment is indeed the final solution.
I will be the 3rd patient he has doing this same program with many more trying to get approvals from their insurance companies.
I should start within a week and will post updates weekly on how I feel and the journey.
Keep the faith and blessings will often happen!
Happy Grammy today for sure!!!
I will be the 3rd patient he has doing this same program with many more trying to get approvals from their insurance companies.
I should start within a week and will post updates weekly on how I feel and the journey.
Keep the faith and blessings will often happen!
Happy Grammy today for sure!!!
Mike
- Q80K affects treatment with Olysio (Simeprevier) a second generation protease inhibitor...not all DAAs.
- Haven't researched DAAs from Abbott and BMS as thoroughly since they are still in trials and can't be taken right now unless in a trial.
- Some data suggests that IL28B genotype may represent an 'easy-to-cure' characteristic for certain IFN-free regimens
"The INFORM-1 study was the first study to demonstrate that IFN-free therapy could have a potent antiviral effect. Patients were treated with a combination of mericitabine (NI) and the danoprevir (PI) for 14 days, before follow-on PR therapy to 48 weeks. Analysis of the on-treatment viral kinetics in 15 patients during the 2 weeks of oral therapy revealed a significant difference in phase-II viral kinetics according to IL28B genotype suggesting that IL28B genotype influences the rate of clearance of infected hepatocytes during IFN-free therapy. This might be consistent with the association between IL28B genotype and spontaneous clearance of HCV"
(Source...Chu TW, Kulkarni R, Gane EJ et al. Effect of IL28B genotype on early viral kinetics during interferon-free treatment of patients with chronic hepatitis C. Gastroenterology 2012; 142: 790–795.)
Another Study...
SOUND-C2 evaluated the combination of BI 201335 (PI), BI 207127 (NNI) ± RBV (Fig. 1a). Interim results demonstrated a clear difference in SVR12 according to IL28B genotype in HCV-1a patients (Fig. 1b,c). The low SVR rates observed in HCV-1a non-C/C patients resulted from virological breakthrough in most patients, suggesting that IL28B genotype influenced the emergence of RAVs.
Source:
Zeuzem S, Soriano V, Asselah T et al. SVR4 and SVR12 with an interferon-free regimen of BI 201335 AND BI 207127, +/− ribavirin, in treatment-naïve patients with chronic genotype-1 HCV infection: interim results of SOUND-C2. J Hepatol 2012;56:Abstract 101.
- Q80K affects treatment with Olysio (Simeprevier) a second generation protease inhibitor...not all DAAs.
- Haven't researched DAAs from Abbott and BMS as thoroughly since they are still in trials and can't be taken right now unless in a trial.
- Some data suggests that IL28B genotype may represent an 'easy-to-cure' characteristic for certain IFN-free regimens
"The INFORM-1 study was the first study to demonstrate that IFN-free therapy could have a potent antiviral effect. Patients were treated with a combination of mericitabine (NI) and the danoprevir (PI) for 14 days, before follow-on PR therapy to 48 weeks. Analysis of the on-treatment viral kinetics in 15 patients during the 2 weeks of oral therapy revealed a significant difference in phase-II viral kinetics according to IL28B genotype suggesting that IL28B genotype influences the rate of clearance of infected hepatocytes during IFN-free therapy. This might be consistent with the association between IL28B genotype and spontaneous clearance of HCV"
(Source...Chu TW, Kulkarni R, Gane EJ et al. Effect of IL28B genotype on early viral kinetics during interferon-free treatment of patients with chronic hepatitis C. Gastroenterology 2012; 142: 790–795.)
Another Study...
SOUND-C2 evaluated the combination of BI 201335 (PI), BI 207127 (NNI) ± RBV (Fig. 1a). Interim results demonstrated a clear difference in SVR12 according to IL28B genotype in HCV-1a patients (Fig. 1b,c). The low SVR rates observed in HCV-1a non-C/C patients resulted from virological breakthrough in most patients, suggesting that IL28B genotype influenced the emergence of RAVs.
Source:
Zeuzem S, Soriano V, Asselah T et al. SVR4 and SVR12 with an interferon-free regimen of BI 201335 AND BI 207127, +/− ribavirin, in treatment-naïve patients with chronic genotype-1 HCV infection: interim results of SOUND-C2. J Hepatol 2012;56:Abstract 101.
Thanks for the info, miss maddie. (Is maddie short for Madeleine or for mad?)
I take "escape variants" to mean any mutated viral sub-species that escapes from drug action.
Coupla questions for you:
- Is Q80K the only mutation that's keeping people from achieving SVR?
- What about the DAAs from Abbott and BMS vis-a-vis mutations?
- As I understand it, the IL28B mutation only affects the outcome of Interferon-based Tx. Is that right?
Thanks for your help with this.
Mike
I take "escape variants" to mean any mutated viral sub-species that escapes from drug action.
Coupla questions for you:
- Is Q80K the only mutation that's keeping people from achieving SVR?
- What about the DAAs from Abbott and BMS vis-a-vis mutations?
- As I understand it, the IL28B mutation only affects the outcome of Interferon-based Tx. Is that right?
Thanks for your help with this.
Mike
Sorry, the above link not working. Just search for Quest diagnostics test #90924, then click on "related education" tab for freq. asked questions, click on name of test on that page and you are brought to a list of questions. Question 4 addresses Q80K.
Hope you all have a great day!
Hope you all have a great day!
Just went to recheck Quest website and the test called Hep C Viral RNA NS3 Genotype (test code 90924) looks like it does test for Q80K polymorphism.
http://education.questdiagnostics.com/faq/FAQ132
http://education.questdiagnostics.com/faq/FAQ132
Not sure exactly what you refer to when you say viral escape variants. If you mean mutations then I can tell you that Olysio has a low resistance to the Q80K polymorphism (mutation) which is naturally occuring in many people with GT1a. In other words, it is there in many GT1 individuals prior to treatment, it does not develop due to treatment. When it is present, it can decrease chances of svr with Olysio. Since you are GT1b, it is almost certain you do not possess this polymorphism. When Sovaldi is added along with Olyisio, in those possessing the Q80K polymorphism, the svr chances may be around 80% according to my hepatologist. This is higher than if it is given with Inf/Riba and possessing Q80K. Since you are GT1b, and most likely without the Q80K mutation, your chances of svr are higher. Sovaldi has high resistance to mutations. Also, does not show any cross resistance problems to date.
Have an Answer?
You are reading content posted in the Hepatitis C Community
Learn about this treatable virus.
Getting tested for this viral infection.
3 key steps to getting on treatment.
4 steps to getting on therapy.
What you need to know about Hep C drugs.
How the drugs might affect you.
These tips may up your chances of a cure.
A list of national and international resources and hotlines to help connect you to needed health and medical services.
Herpes sores blister, then burst, scab and heal.
Herpes spreads by oral, vaginal and anal sex.
STIs are the most common cause of genital sores.
Condoms are the most effective way to prevent HIV and STDs.
PrEP is used by people with high risk to prevent HIV infection.
